Alzheimer’s wonder drug faces NHS block over cost
The most effective drug for Alzheimer’s will be blocked for use on the NHS on Wednesday. Regulators are expected to declare the new treatment for the disease safe for use but the rationing body for the health service will immediately rule that it is too expensive for NHS patients.
Eli Lilly & Co. closed $63.38 below its 52-week high ($972.53), which the company reached on August 22nd.
Eli Lilly sued three medical spas and online vendors for selling products that claim to contain the ingredient in its ...
Led by Sen. Dick Durbin of Illinois, senators question if direct-to-consumer website telehealth deals are a new way around ...
A group of U.S. senators are digging into the direct-to-consumer telehealth platforms launched by Eli Lilly and Pfizer this ...
Eli Lilly sues vendors for selling unauthorized tirzepatide amid resolved shortages. Lawsuits target vendors offering ...
Spirit Airlines (SAVE) extends its debt refinancing deadline with the US Bank National Association, sending the stock soaring ...
Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.
Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...
Eli Lilly is expanding its innovation digs to Beijing, opening two research centers called the Eli Lilly China Medical ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Dick Durbin (D-Ill.) demanded answers from Pfizer and Eli Lilly about their relationships with the telehealth prescribers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback